Zenas BioPharma (ZBIO) Interest & Investment Income (2025 - 2026)
Zenas BioPharma's (ZBIO) quarterly Interest & Investment Income came in at $3.0 million in Q1 2026, down 11.08% year-on-year from $3.4 million in Q1 2025, and up 3720.25% quarter-over-quarter from $79000.0 in Q4 2025.
Zenas BioPharma (ZBIO) Interest & Investment Income (2025 - 2026) Analysis & Trends
Zenas BioPharma's Interest & Investment Income history runs 2 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 11.08% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $156000.0, down 98.04% from the prior year.
- Interest & Investment Income grew to $3.0 million in Q1 2026 per ZBIO's latest filing, from $79000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.4 million in Q1 2025 and bottomed at $30000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Zenas BioPharma | 1.82 Bn | 1.10 Bn | - | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.02 Mn |
| Dec 31, 2025 | 79,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 3.39 Mn |